ImmunityBio, Inc. (IBRX) Misses Q1 EPS by 2c
Tweet
Share
E-mailGet Alerts IBRX Hot Sheet
Join SI Premium – FREE
ImmunityBio, Inc. (NASDAQ: IBRX) reported Q1 EPS of ($0.15), $0.02 worse than the analyst estimate of ($0.13). Revenue for the quarter came in at $16.5 million versus the consensus estimate of $16.86 million.
For earnings history and earnings-related data on ImmunityBio, Inc. (IBRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Barclays Upgrades Poste Italiane SpA (PST:IM) (PITAF) to Overweight
- Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
